Sutro Biopharma (STRO) Non-Current Assets (2017 - 2026)

Sutro Biopharma has reported Non-Current Assets for 9 years, with the latest figure at $22.9 million in Q4 2025.

• Quarterly Non-Current Assets fell 47.82% year-over-year to $22.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $115.2 million (down 37.51% YoY) and the FY2025 annual result came in at $22.9 million, down 47.82% from the prior year.
• Non-Current Assets retreated to $22.9 million in Q4 2025 per STRO's latest filing, from $27.5 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $122.9 million in Q4 2021 and troughed at $22.9 million in Q4 2025.
• A 5-year average of $58.1 million and a median of $51.7 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2021 and 2022: Non-Current Assets surged 708.24% in 2021, then plunged 56.23% in 2022.
• Over 5 years, Non-Current Assets stood at $122.9 million in 2021, then plunged by 56.23% to $53.8 million in 2022, then decreased by 8.55% to $49.2 million in 2023, then declined by 10.77% to $43.9 million in 2024, then tumbled by 47.82% to $22.9 million in 2025.
• According to Business Quant data, Non-Current Assets over the past three periods registered $22.9 million, $27.5 million, and $30.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.